Literature DB >> 17011612

Ankylosing spondylitis: a contemporary perspective on diagnosis and treatment.

Mark Mansour1, Gurtej S Cheema, Stanley M Naguwa, Adam Greenspan, Andrea T Borchers, Carl L Keen, M Eric Gershwin.   

Abstract

OBJECTIVES: In recent years, great progress has been made in the development of diagnostic tools, therapeutic approaches, and validated outcome measures in the understanding of the pathogenesis of ankylosing spondylitis (AS). The purpose of this review was to summarize these developments.
METHODS: We performed a PubMed search for the period 1978 to 2005, using the keyword, "ankylosing spondylitis," resulting in a total of 4878 publications, including 778 reviews. Articles were then selected based on their discussion of recent diagnostic tools and new treatment approaches in the pathogenesis of AS, leading to a final total of 104 articles.
RESULTS: In recent years, there have been 2 major developments in the management of AS that make earlier diagnosis possible and offer the hope of alleviating pain and preventing structural changes that result in loss of function. These developments include the use of magnetic resonance imaging to visualize the inflammatory changes in the sacroiliac joint and the axial spine, and the demonstration that tumor necrosis factor blocking agents are highly efficacious in reducing spinal inflammation and possibly in slowing radiographic progression.
CONCLUSIONS: There have been major advances in both the diagnostic tools and the therapeutic regimens available for patients with AS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17011612     DOI: 10.1016/j.semarthrit.2006.08.003

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  10 in total

1.  Screening and evaluating the mimic peptides as a useful serum biomarker of ankylosing spondylitis using a phage display technique.

Authors:  Min Wang; Xianping Li; Jingwei Chen; Yong Zhou; Hong Cao; Xiang Wu; Hongmin Jiang
Journal:  Rheumatol Int       Date:  2010-03-19       Impact factor: 2.631

2.  HLA-B27 homodimers and free H chains are stronger ligands for leukocyte Ig-like receptor B2 than classical HLA class I.

Authors:  Joanna Giles; Jackie Shaw; Christopher Piper; Isabel Wong-Baeza; Kirsty McHugh; Anna Ridley; Demin Li; Izabela Lenart; Antony N Antoniou; Katilin DiGleria; Kimiko Kuroki; Katsumi Maenaka; Paul Bowness; Simon Kollnberger
Journal:  J Immunol       Date:  2012-05-16       Impact factor: 5.422

3.  Delayed presentation and diagnosis of cervical spine injuries in long-standing ankylosing spondylitis.

Authors:  Fahim Anwar; A Al-Khayer; G Joseph; M H Fraser; M V Jigajinni; D B Allan
Journal:  Eur Spine J       Date:  2010-12-03       Impact factor: 3.134

4.  The effects of β-D-mannuronic acid (M2000), as a novel NSAID, on COX1 and COX2 activities and gene expression in ankylosing spondylitis patients and the murine monocyte/macrophage, J774 cell line.

Authors:  Fahimeh Jafarnezhad-Ansariha; Mir Saeed Yekaninejad; Ahmad-Reza Jamshidi; Reza Mansouri; Mahdi Vojdanian; Mahdi Mahmoudi; Mohammad Javad Fattahi; Seyed Naser Hashemi; Bernd H A Rehm; Hidenori Matsuo; Emanuela Esposito; Salvatore Cuzzocrea; Abbas Mirshafiey
Journal:  Inflammopharmacology       Date:  2017-08-17       Impact factor: 4.473

5.  Serum levels of IL-33 is increased in patients with ankylosing spondylitis.

Authors:  Guo-Wei Han; Li-Wen Zeng; Chun-Xiang Liang; Bai-Ling Cheng; Bing-Sheng Yu; Hao-Miao Li; Fang Fang Zeng; Shao-Yu Liu
Journal:  Clin Rheumatol       Date:  2011-10-04       Impact factor: 2.980

6.  Effects of some acupoints (Du-14, Li-11, St-36, and Sp-6) on serum TNF-α and hsCRP levels in healthy young subjects.

Authors:  Saliha Karatay; Fatih Akcay; Kadir Yildirim; Fazile Hatipoglu Erdem; Filiz Alp
Journal:  J Altern Complement Med       Date:  2011-03-27       Impact factor: 2.579

7.  Association of adipokines, interleukin-6, and tumor necrosis factor-α concentrations with clinical characteristics and presence of spinal syndesmophytes in patients with ankylosing spondylitis: A cross-sectional study.

Authors:  Laura Gonzalez-Lopez; Nicte S Fajardo-Robledo; A Miriam Saldaña-Cruz; Inocente V Moreno-Sandoval; David Bonilla-Lara; Soraya Zavaleta-Muñiz; Arnulfo Hernan Nava-Zavala; Paulina Hernandez-Cuervo; Alberto Rocha-Muñoz; Norma Alejandra Rodriguez-Jimenez; Maria L Vazquez-Villegas; J Francisco Muñoz-Valle; Mario Salazar-Paramo; Ernesto G Cardona-Muñoz; Jorge I Gamez-Nava
Journal:  J Int Med Res       Date:  2017-05-23       Impact factor: 1.671

8.  Disease Activity, Occupational Participation, and Quality of Life for Individuals with and without Severe Fatigue in Ankylosing Spondylitis.

Authors:  Deirdre Connolly; Clodagh Fitzpatrick; Finbar O'Shea
Journal:  Occup Ther Int       Date:  2019-07-01       Impact factor: 1.448

9.  [Ankylosing spondylitis in Senegal: epidemiological, diagnostic, therapeutic and evolutionary features at the Hospital Center University Aristide Le Dantec, Dakar].

Authors:  Abbasse Abba; Moustapha Niasse; Ladji Mohamed Diaby; Hassan Ali
Journal:  Pan Afr Med J       Date:  2021-09-06

10.  Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN).

Authors:  Joachim Sieper; Jürgen Braun; Jonathan Kay; Salvatore Badalamenti; Allen R Radin; Lixia Jiao; Stefano Fiore; Tanya Momtahen; George D Yancopoulos; Neil Stahl; Robert D Inman
Journal:  Ann Rheum Dis       Date:  2014-02-18       Impact factor: 19.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.